Articles tagged with Prostate Tumors
Researchers detected a novel virus, XMRV, in human prostate tumors with two copies of the RNASEL gene mutation. The study validates the use of DNA-hunting 'virus chip' technology to discover previously unknown viruses and potentially uncover new viral causes for disease.
Research reveals omega-6 fatty acids stimulate inflammatory genes associated with cancer, particularly in prostate tumors. Studies found that adding omega-6 to growth medium doubled tumor growth compared to control groups.
Researchers found that the combination of curcumin and PEITC significantly retards prostate cancer tumor growth in laboratory mice. The discovery suggests potential for using plant-based compounds as alternative therapies to treat advanced prostate cancers.
A study found that Ack1 is a key driver of tumor growth in prostate cancer, and its inhibition can slow tumor formation. The researchers also discovered an experimental drug called geldanamycin that can inhibit Ack1 activity by interfering with its molecular interactions.
A study by Case Western Reserve University researchers found that apigenin, a plant flavonoid, slowed tumor growth in mice with prostate cancer. Apigenin also reduced IGF-1 levels associated with increased cancer risk and triggered cell self-destruction.
A study found that nearly 60% of prostate cancer specimens received higher Gleason scores than original assignments, suggesting that pathologists are more likely to assign high scores to contemporary tumor samples. This 'Will Rogers phenomenon' may lead to a false sense of therapeutic accomplishment and skew mortality rates.
Researchers found ER-positive/PR-negative tumors may be more aggressive and respond poorly to tamoxifen, while EDNRB mutations are linked to melanoma risk. Farnesyltransferase inhibitors show promise against aerodigestive tract cancer cells.
Researchers found that omega-6 fatty acids can stimulate cell growth in prostate cancer cells by activating the production of cPLA2 and COX2 enzymes. A diet high in omega-6 fatty acids may contribute to increased risk of prostate cancer, while a new class of drugs targeting cPLA2 could offer a safer alternative to existing treatments.
Researchers investigated the roles of PTEN and TSC2 in tumorigenesis and found that TSC2 can suppress specific tumors caused by Pten heterozygosity. However, PTEN is haploinsufficient for repression of carcinogenesis resulting from Tsc2 heterozygosity.
Researchers discovered elevated GABA levels in aggressive neuroendocrine tumors, which may indicate poor prognosis. The study suggests a unique tumor-associated pattern that could provide new ways to diagnose these cancers earlier and implement more effective treatments.
A new study has shown that PET with 11C-Choline improves the early diagnosis of relapsed prostate cancer, with a sensitivity of 65% compared to 28% for conventional FDG. This finding is particularly useful for detecting relapses in patients with low PSA levels.
Researchers at McMaster University are studying the connection between hormone and protein levels in prostate cancer progression. The study focuses on two proteins, PTEN and Beta-catenin, which may play a crucial role in preventing tumor formation.
Researchers have discovered a synthetic cell-signaling molecule called Enigmols that suppresses the growth of human cell lines representing multiple types of cancer and reduces tumors in animal studies. The findings suggest that Enigmols may be a new approach to treating cancer, with potential benefits including minimal side effects.
A study found that analyzing prostate tissue's metabolic profile can identify the biologic status of the disease, allowing clinicians to make better-informed decisions on treatment. The technique outperformed standard histopathology in differentiating between cancer cells and benign cells.
A gene mutation that protects against malaria has been found to increase the risk of aggressive prostate cancer in African-American men. Researchers discovered that mice with this mutation developed larger, more aggressive tumors due to increased angiogenic chemokine production.
Researchers created tumor-specific immune cells that were insensitive to TGF-beta, a powerful substance that helps cancer cells evade the immune system. These cells were able to infiltrate and destroy tumors effectively, while preventing autoimmune disease, offering new hope for treating advanced prostate cancer.
The study found finasteride reduced the incidence of prostate cancer by 24.8% compared to a placebo, potentially saving thousands of lives over ten years. Despite an increase in high-grade tumors, the analysis shows that this benefit outweighs the potential drawbacks.
The Journal of Nuclear Medicine Supplement offers a comprehensive overview of radionuclide therapy, including its applications in thyroid cancer, lymphoma, and other diseases. The supplement highlights the growing importance of nuclear medicine in patient care and provides insight into emerging trends and technologies.
A team of researchers has discovered a new form of vascular endothelial growth factor (VEGF) called VEGF165b, which inhibits the growth of new blood vessels required for tumours to grow above one millimetre. This protein is found in normal tissues and can prevent cancer growth by starving tumours of nutrients.
Researchers discovered a previously undiscovered variant of tumor-suppressor TrkA, called TrkIII, associated with childhood cancer progression. Elevated TrkIII levels in advanced stage tumors suggest its role in cancer progression, and preventing its generation may inhibit disease progression.
Researchers developed an image translation system to bridge the gap between advanced diagnostic techniques and radiation treatment planning systems. The system facilitates biological optimization planning, using information about cancer cell location and density to deliver escalated doses of radiation.
Researchers have found that low-dose synthetic lycopene alone can suppress the growth of human prostate tumors by over half. A combination of low-dose lycopene and vitamin E was shown to be even more effective in inhibiting tumor growth, with a significant reduction in PSA levels.
Researchers found that prostate cancer cells shed immunostimulatory molecules, allowing them to evade the immune system's natural killer cell defense. Soluble MIC levels in serum correlated with high-grade and invasive tumor status, suggesting a potential biomarker for disease progression.
Researchers found that AMPK plays a vital role in protecting cells under conditions of a heart attack, including glucose uptake and preventing cardiac dysfunction. In contrast, mice without functional AMPK exhibited impaired contractile function and increased cell death after blood flow reduction.
Scientists successfully designed and tested nanoparticles to both target and visualize prostate tumors in mice, offering potential for early cancer detection and treatment. The breakthrough uses a unique coating to protect the particles from degradation and enhance their targeting capabilities.
Scientists at the Pacific Northwest Research Institute discovered evidence for DNA structure characteristic of metastasis in prostates with metastazing tumors. Early detection is crucial in fighting cancer, and this finding could lead to a new powerful weapon against cancer spread.
Two projects aim to study angiogenesis and anti-angiogenic therapy, as well as the interaction between hormones and growth factors in prostate tumor growth. The ultimate goal is to develop new treatment strategies that suppress metastases by prolonging dormant states.
A novel compound called ZK-CDK has been shown to inhibit both tumour cell growth and angiogenesis in human cancer cells. The compound was tested on mice models and found highly efficacious, particularly in slow-growing hormone-independent breast and prostate tumours.
The study found that transvaginal ultrasound provides superior imaging of the rectum and surrounding tissues, resolving rectal wall layers more clearly. Additionally, it is easier to perform with conventional ultrasound probes and causes less patient discomfort.
A new imaging probe detects small tumors in the brain, providing crucial information to surgeons during operations. The technology uses near-infrared fluorescence optical imaging to identify tumor margins and improve surgical treatment.
Researchers found that galectin-1, a molecule present in various tumor types, negatively impacts T cell survival and contributes to tumor progression. Inhibition of galectin-1 significantly reduces tumor formation in mice, highlighting its potential as a molecular target for cancer immunotherapy.
A team of scientists at Rutgers University has identified the active compound in croton plant oil, TPA, which shows promise in treating prostate cancer. The study found that TPA can stop new cells from growing, kill existing cancer cells, and shrink prostate tumors.
Researchers found that ginger compounds slowed tumor development in mice, while Scutellaria barbata inhibited apoptosis in prostate cancer cells. These findings suggest potential chemopreventive effects of these natural herbs against certain cancers.
Researchers created mouse models to study PTEN's impact on prostate cancer progression. Subtle reductions in PTEN dose produced progressive changes in the biology of tumors, with mice having no functional PTEN genes showing the most invasive and aggressive cancers.
Researchers at UT Southwestern Medical Center have discovered that certain enzyme inhibitors can slow tumor growth by inhibiting telomerase, an enzyme that maintains DNA sequences. The study found that these inhibitors can be used in combination with standard cancer therapies to slow or prevent recurrence of tumors.
Finasteride has been shown to prevent prostate cancer in both low-risk and high-risk men. However, those on finasteride were more likely to develop high-grade cancers.
Functional MRI can help identify tumor heterogeneity and biological quirks that predict response to treatment. The imaging technology offers insight into a tumor's character beyond its superficial structure, enabling targeted therapies for specific sites.
Researchers found that PPAR-g is abundantly expressed in human pituitary tumors, including non-functioning and hormone-secreting types. The study suggests that PPAR-g binding compounds may be suitable oral therapies for these tumors.
A new technique developed by Malins' laboratory uses Fourier transform-infrared spectroscopy to analyze DNA from prostate tumor biopsies, allowing doctors to identify patients at high risk for metastasis. This breakthrough enables more informed treatment decisions and potentially saves lives.
A study found that 11C-Choline PET scans were more sensitive in detecting pelvic lymph node tumors and accurately staged their development, with an overall accuracy of 93%. This technique shows promise as a safe, non-invasive method for prostate cancer patients
A new gene therapy approach has been shown to virtually eliminate cancerous tumors in mice by boosting their immune systems. The treatment, which blocks a key immunosuppressor called TGF-beta, resulted in 70-80% survival rates in mice with melanoma and prostate cancer.
Researchers at Cedars-Sinai Medical Center have found that a potent experimental drug called 2C4 slows tumor growth in both breast and prostate cancer tumors in mice, even when small amounts of HER-2/neu are expressed. The study's findings may lead to a new way to treat breast and prostate cancers.
A new test measures the ratio of cathepsin B to inhibitor stefin A in prostate tissue, revealing differences in tumors not visible under the microscope. The test can identify biologically aggressive and less aggressive forms of cancer, guiding treatment decisions for patients.
Researchers have developed a new technique using the vascular endothelial growth factor (VEGF) as a carrier to deliver a toxic agent selectively to tumor blood vessels. This approach has shown impressive anti-tumor effects in mice with human melanoma and prostate cancer, reducing tumor growth by up to 16 percent.
Researchers at UIC are testing a new vaccine for advanced prostate cancer, targeting patients with a specific immune type. The vaccine uses a fragment of the protein PSA to stimulate the immune system and destroy tumor cells.
Researchers have identified new markers for prostate and colon cancers, as well as a potential tumor suppressor gene. TIG1 was found to be expressed in normal prostate tissue but not malignant tumors, suggesting it may play a role in cancer progression.
Researchers discovered that Nox1 enzyme generates reactive oxygen molecules that trigger angiogenesis and tumor growth. Inhibiting Nox1 activity or reducing hydrogen peroxide levels may decrease cancer cell growth and increase sensitivity to chemotherapy.
Researchers have created nanoscale atomic generators that selectively destroy cancer cells without harming healthy tissue. The generators use radioactive actinium to produce potent alpha particles that kill cancer cells, offering a new hope for treating various types of cancer.
Researchers at Yale University have developed a novel molecule that eradicates cancer by destroying tumor blood vessels. The icon targets the inner surface of tumors expressing tissue factor, allowing it to bind and activate an immune response against cancer cells.
Researchers at the University of Florida have developed a new radiation-targeting system that uses advanced imaging and optic guidance techniques to precisely target tumors. The system, now commercially available, aims to minimize damage to surrounding healthy tissues and potentially improve cure rates.
A new pilot study suggests that a combination of a low-fat diet and flaxseed supplement may be protective against prostate cancer. The researchers found significant decreases in cholesterol levels and testosterone, as well as lower proliferation rates and higher apoptosis rates in tumor cells among those on the diet.
Researchers found that celecoxib reduced breast tumor incidence by 68% and average tumor size by 81% in rats. The anti-tumor effects of celecoxib are attributed to its ability to inhibit an enzyme that promotes cancer growth.
Scientists at the University of Rochester Medical Center are exploring the use of genetic algorithms to treat prostate cancer by improving how radiation is delivered. The formulas have been developed by medical physicist Yan Yu, Ph.D., who heads a task force on the subject for the American Association of Physicists in Medicine.
Researchers at Memorial Sloan-Kettering Cancer Center challenge current understanding of prostate cancer treatment by showing that testosterone withdrawal triggers a dormant state in tumor cells, rather than causing widespread cell death. This study offers new hope for developing targeted therapies to combat recurrent prostate cancer.
Men with specific chromosome 8 abnormalities have a 30% survival rate after 10 years, compared to 78% for those with normal chromosomes. The findings could help identify patients who require closer follow-up and more aggressive early treatment.
A new animal study suggests that soy isoflavones may slow prostate cancer growth by inhibiting cell proliferation and promoting apoptosis. The study also found lower levels of insulin-like growth factor 1, a hormone that stimulates tumor growth.
Researchers at UNC-CH will investigate prostate cancer mechanisms, including the role of androgens, to develop a potential cure. The team aims to understand why black men develop prostate cancer twice as often as white men do.
Researchers found that losing function of one copy of the PTEN tumor suppressor gene can lead to chronic fatal conditions, including cancer and autoimmune diseases. The study showed that this disruption allows white blood cells to accumulate unchecked and attack their own organs.
Research at Ohio State University found that a low-calorie diet slowed tumor growth in rats and mice with prostate cancer. The study suggested that maintaining proper energy balance may inhibit prostate cancer progression.
ABX-EGF targets the receptor for human epidermal growth factor (EGFr), which is overexpressed on many major human tumor types. The antibody eradicates established tumors with low doses and has minimal immunogenicity.